BeOne Medicines Ltd (6160) Gets a Buy from Nomura
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 million
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform Rating
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLC